LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patie
First medicine targeting BRCA mutations to show clinical benefit in adjuvant settingWILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced results from the OlympiA Phase III trial showed LYNPARZA® (olaparib) demonstrated a statistically significa...